A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

• Status: Completed
• Trial end date: 2008-07-01

Summary

This was a phase I dose escalation trial designed to determine the maximum tolerated dose (MTD) for the combination of romidepsin (depsipeptide) and gemcitabine. The study was originally planned as a Phase I/II; however only Phase I of the study was conducted.

• Phase: Phase 1

Details

• Lead Sponsor: Celgene; Celgene Corporation
• Treatments: Gemcitabine; Romidepsin